Mark Rusznak1, R Stokes Peebles. 1. Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to describe the recent advances that have been made in understanding the protective role of prostaglandin E2 (PGE2) in aspirin-exacerbated respiratory disease (AERD), known in Europe as NSAID-exacerbated respiratory disease (N-ERD). RECENT FINDINGS: Decreased PGE2 signaling through the EP2 receptor in patients with AERD leads to an increase in leukotriene synthesis and signaling. Leukotriene signaling not only directly activates group 2 innate lymphoid cells and mast cells, but it also increases production of IL-33 and thymic stromal lymphopoietin. These cytokines drive Th2 inflammation in a suspected feed-forward mechanism in patients with AERD. SUMMARY: Recent discoveries concerning the role of PGE2 in leukotriene synthesis and signaling in AERD, as well as downstream effects on group 2 innate lymphoid cells and mast cells, allow for a more comprehensive understanding of the pathogenesis of this disease. These discoveries also identify new paths of potential investigation and possible therapeutic targets for AERD.
PURPOSE OF REVIEW: The purpose of this review is to describe the recent advances that have been made in understanding the protective role of prostaglandin E2 (PGE2) in aspirin-exacerbated respiratory disease (AERD), known in Europe as NSAID-exacerbated respiratory disease (N-ERD). RECENT FINDINGS: Decreased PGE2 signaling through the EP2 receptor in patients with AERD leads to an increase in leukotriene synthesis and signaling. Leukotriene signaling not only directly activates group 2 innate lymphoid cells and mast cells, but it also increases production of IL-33 and thymic stromal lymphopoietin. These cytokines drive Th2 inflammation in a suspected feed-forward mechanism in patients with AERD. SUMMARY: Recent discoveries concerning the role of PGE2 in leukotriene synthesis and signaling in AERD, as well as downstream effects on group 2 innate lymphoid cells and mast cells, allow for a more comprehensive understanding of the pathogenesis of this disease. These discoveries also identify new paths of potential investigation and possible therapeutic targets for AERD.
Authors: Roel G J Klein Wolterink; Alex Kleinjan; Menno van Nimwegen; Ingrid Bergen; Marjolein de Bruijn; Yelvi Levani; Rudi W Hendriks Journal: Eur J Immunol Date: 2012-05 Impact factor: 5.532
Authors: Jacqueline J Eastman; Kellen J Cavagnero; Adam S Deconde; Alex S Kim; Maya R Karta; David H Broide; Bruce L Zuraw; Andrew A White; Sandra C Christiansen; Taylor A Doherty Journal: J Allergy Clin Immunol Date: 2017-03-06 Impact factor: 10.793
Authors: Gordon S Wong; Jamie L Redes; Nariman Balenga; Morgan McCullough; Nathalie Fuentes; Ameya Gokhale; Cynthia Koziol-White; Joseph A Jude; Laura A Madigan; Eunice C Chan; William H Jester; Sabrina Biardel; Nicolas Flamand; Reynold A Panettieri; Kirk M Druey Journal: J Allergy Clin Immunol Date: 2020-03-19 Impact factor: 10.793